Syngene International Limited

rs 1

assumptions do not come to fruition. Putting Science to Work 2 Agenda Sr. no Timing Particulars 1:30 - 1:40 PM Why this webinar Introduction to our inhouse expert - Dr. Mrinal Kammili 1:40 PM -

9%

d growing segment within the overall global CRDMO market Global CRDMO market expected to grow at ~9% CAGR Key growth drivers of Clinical CRO market Overall CRDMO Market Size (USD Bn) 330 370 320

10%

029F Market Segment (USD Bn) Pre-Clinical CRO1 Clinical CRO Overall CDMO2 50 Scale adjusted 10% CAGR 41 26 0 0 11% CAGR 99 59 8% CAGR 190 129 200 100 2024 2029 2024 2029 2024 202

11%

D Bn) Pre-Clinical CRO1 Clinical CRO Overall CDMO2 50 Scale adjusted 10% CAGR 41 26 0 0 11% CAGR 99 59 8% CAGR 190 129 200 100 2024 2029 2024 2029 2024 2029 Clinical CROs market

8%

l CRO1 Clinical CRO Overall CDMO2 50 Scale adjusted 10% CAGR 41 26 0 0 11% CAGR 99 59 8% CAGR 190 129 200 100 2024 2029 2024 2029 2024 2029 Clinical CROs market forms ~30% of ove

30%

99 59 8% CAGR 190 129 200 100 2024 2029 2024 2029 2024 2029 Clinical CROs market forms ~30% of overall CRDMO market and growing at double digit Source : Evaluate Pharma, Frost & Sullivan, IM

7%

s both Large molecule and Small molecule CDMO 1 2 3 4 5 Increasing R&D Pipeline: growing at ~7% CAGR; new drugs require clinical trials for regulatory approvals Outsourcing Acceleration: Big ph

13%

ging markets increasing share, especially in early phase and patient-diverse studies 5-yr CAGR 13% 9% 18% 6% 11% LATAM & Carribean MEA APAC Europe North America 2024 2029 Factor Level

18%

ets increasing share, especially in early phase and patient-diverse studies 5-yr CAGR 13% 9% 18% 6% 11% LATAM & Carribean MEA APAC Europe North America 2024 2029 Factor Level of attra

6%

increasing share, especially in early phase and patient-diverse studies 5-yr CAGR 13% 9% 18% 6% 11% LATAM & Carribean MEA APAC Europe North America 2024 2029 Factor Level of attractiv

16%

market1 – Exceeds global growth rate Indian clinical CRO market – Factors driving growth ($Bn) 16% CAGR 3.4 1.9 2024 2028 India’s clinical CRO market is projected to grow at 16% CAGR (2024 –

40%

geopolitical dynamics – China+1, US bio secure act • India Provides significant cost advantage - ~40% to 60% compared to North America & Europe Source: Frost & Sullivan, Industry reports 1 Includes BA

Key success factors for Indian players include

1

Key success factors for Indian players include

• Understanding of local market and regulations: Increased drug development complexities and heterogenous regulatory compliance for different markets • Full-service offerings: Sponsors are increasingly seeking a comprehensive solution for all their drug development requirements. • Access to large patient population and track record of delivering studies within the cost, timelines and global compliance standards • Investments in new modalities: Emerging modalities such as biologics/ADC require deeper translational insights—multi-omics data, mechanistic biomarkers, advanced bioanalytical platforms • Use and data and analytics: advanced digital platforms, data analytics, and AI-driven trial management, ensuring efficiency, precision, and data integrity at every stage Putting Science to Work 9 Translational and Clinical Research forms an integral part of the overall drug discovery and development value chain Discovery Development Commercialization Target Identification Lead Generation Targ